What Albisec Treats: Main Uses and Benefits

Albisec is considered relevant in situations involving polymicrobial genital infections, which often involve the simultaneous presence of two different types of pathogens, such as Candida fungi and susceptible anaerobic bacteria or protozoa like Trichomonas vaginalis. This dual approach is applicable within clinical settings marked by heightened patient distress and is used in areas where short-term symptom management is appropriate for dual-pathogen contexts. Secnidazole, a key component of the formulation, is used to address conditions like bacterial vaginosis and trichomoniasis.

The medication helps address symptom clusters that may become intense or disruptive and create noticeable interference with daily stability. It is used for managing the pronounced manifestations of vulvovaginitis, including intense vaginal itching (pruritus), burning sensations, redness, and swelling. By addressing the pathogens associated with the condition, it contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Albisec is commonly applied in conditions like Vulvovaginal Candidiasis, Bacterial Vaginosis, and Trichomoniasis. Its application is often relevant in situations requiring short-term symptomatic assistance for recurrent or complex cases, as well as in the treatment of sexual partners for conditions like Trichomoniasis. It provides supportive relief that may assist with maintaining functional stability during difficult symptomatic periods.

“This therapeutic approach is relevant in contexts marked by increased discomfort or tension and assists with maintaining functional stability during difficult episodes.”

Quick Fact: Relevant for managing Inflammatory Discomfort

Regulatory References

1. National Library of Medicine’s MedlinePlus overview of Secnidazole

Eligibility Scope

• Populations for whom use is allowed: Adult patients, as the safety and efficacy profile is established primarily for this age group.
• Populations for whom use is contraindicated:
  • Patients with known hypersensitivity to Itraconazole, Secnidazole, or other nitroimidazole derivatives.
  • Individuals with a history of ventricular dysfunction or congestive heart failure (CHF).
  • Patients diagnosed with Cockayne syndrome.
• Pregnancy and lactation eligibility status: Use is contraindicated in pregnancy. Women of childbearing potential must use highly effective contraception during treatment and for two months following the final dose. Use is not recommended while breastfeeding and for 96 hours after the final dose.
• Age-related and condition-specific rules: Safety and efficacy have not been established in pediatric patients. Caution and close monitoring are required for patients with pre-existing hepatic impairment (liver dysfunction) or renal impairment.

---

Eligibility Classifications

• Eligibility severity classification: The medicine carries a formal Contraindicated classification for specific cardiac and hypersensitivity conditions.
• Eligibility-context constraints: Eligibility is defined by prohibitions related to cardiac history, hepatic function, and the reproductive status of women of childbearing potential.

---

Connection to the overall eligibility profile: The regulatory profile strictly defines non-eligibility by combining the highest-risk restrictions of both active components. This formally restricts the medicine to the adult population and absolutely excludes those who are pregnant or have specified cardiac or genetic conditions, requiring use to be conditional for patients with compromised organ function.

Interactions with other medicines and products

Albisec is a Fixed-Dose Combination containing Itraconazole and Secnidazole, and its interaction profile is defined by the regulatory restrictions of both active ingredients. The Itraconazole component is classified as a strong inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and P-glycoprotein (P-gp). This interaction mandates that co-administration with numerous medicines that are substrates for these systems is either contraindicated or requires extreme caution, as it can lead to significantly increased plasma exposure of the co-administered drug.

Documented Restrictions and Timing Rules

Formal restrictions officially prohibit the use of Itraconazole with high-risk medicines like Cisapride, Lovastatin, and Simvastatin due to the risk of severe cardiac or musculoskeletal outcomes. The Secnidazole component carries a separate restriction: consumption of alcoholic beverages or products containing ethanol must be avoided during therapy and for at least two days (48 hours) after the last dose, based on the risk of a pharmacodynamic reaction. For the Itraconazole capsule, optimal absorption requires that it be taken with a meal. Furthermore, co-administration with gastric acid suppressors necessitates a mandatory two-hour separation period to prevent a reduction in Itraconazole's absorption. Some contraindications are also conditional, such as the prohibition of co-administering Itraconazole with drugs like Colchicine in patients with documented renal or hepatic impairment.

How Albisec Works: A Dual-Mechanism Pharmacological Strategy

Albisec is defined by the additive action of two distinct, complementary mechanisms targeting microbial viability. The Itraconazole component acts as a selective inhibitor of lanosterol 14alpha-demethylase, a fungal cytochrome P450 enzyme essential for ergosterol biosynthesis. This molecular inhibition prevents the formation of functional ergosterol and simultaneously causes an accumulation of toxic sterols, resulting in the loss of fungal cell membrane integrity, which is a critical determinant of cell viability.

In parallel, the Secnidazole component is a prodrug activated by nitroreductase enzymes found within susceptible anaerobic microbes. This activation generates highly reactive nitro radical anions that rapidly target the pathogen’s DNA. This genotoxic mechanism induces strand breaks and halts the microbial cell’s ability to replicate or synthesize essential proteins, resulting in microbial cell necrosis. The dual-pathway interference provides coverage across distinct pathogen classes, supporting the systemic elimination of microbes.

Official Administration Guidelines

Albisec is administered via the oral route, utilizing a fixed-dose combination provided in a solid oral form, such as a capsule or tablet. The use of this combination is primarily structured around an ultra-short-term course, often consisting of a single, high-dose administration. This distinct frequency pattern aligns with established protocols for the Secnidazole component, which is prescribed as a single 2-gram dose for conditions like bacterial vaginosis and trichomoniasis.

Key Administration Conditions and Constraints

Instruction Field	Principle of Use
Dosing Schedule	Administered as a single, once-off dose or a very short course, reflecting the need for prompt systemic exposure.
Form Handling	The solid oral form must be swallowed whole and should not be crushed, broken, or chewed. This procedural rule is necessary to maintain the integrity of the formulation and ensure correct absorption.
Timing	Product labeling for the two components provide varying instructions regarding meals. Users follow specific guidance provided with the particular product, which may specify intake with food (for Itraconazole) or without regard to meals (for Secnidazole).
Age-Group Use	Use of the Secnidazole component is generally authorized for adolescent patients aged 12 years and older.
Procedural Context	For certain conditions, such as Trichomoniasis, protocols mandate the simultaneous treatment of the sexual partner as an essential part of the complete use regimen.

This standardized protocol defines the medicine as a high-concentration, single-day oral intervention. These guidelines are designed to ensure the correct procedural use and systemic delivery of both antimicrobial agents concurrently.

Research Evidence / Overview of Studies for Albisec

---

Evidence for Use in Polymicrobial Genital Infections

Research has explored the use of the fixed-dose combination (FDC) in conditions characterized by fluctuating or episodic manifestations, specifically those involving both fungal pathogens and the types of bacterial or protozoal pathogens studied. These studies were primarily short-term clinical trials and small-scale comparative studies focused on adult women. Researchers examined how symptoms evolved in the observed populations and monitored outcomes related to perceived changes in physical discomfort and laboratory measurement of pathogen status.

The findings describe patterns observed in the studies regarding both the clinical and microbiological outcomes measured during the study period. Trials reported on the assessment of symptom change and the measurement of pathogen clearance. Studies reported measurements of changes observed during the immediate follow-up period; however, evidence remains limited and certainty remains low when extrapolating these findings broadly.

---

Trial Design and Comparator Studies

The research examined the FDC mainly through open-label clinical studies. The populations studied included adult women of reproductive age observed with these specific conditions. While research explored the FDC against other existing therapeutic approaches, comparative evidence is lacking in the form of a dominant number of large-scale, blinded Randomized Controlled Trials (RCTs) that directly compare the FDC to other regimens. The study results reflect the specific conditions and parameters under which they were conducted.

---

Long-Term Evidence and Durability of Response

Research monitored responses over defined time intervals, but a significant research limitation is that follow-up durations were limited in most existing studies. There is limited information for long-term outcomes, such as the sustained maintenance of pathogen clearance or the prevention of recurrence beyond the initial follow-up periods described by the researchers. Therefore, long-term effects and the durability of response are not fully established.

---

Evidence in Special Populations

Data for certain groups remain insufficient. Few data are available for specific populations such as adolescents, older adults, or women with certain pre-existing comorbid conditions. Existing studies provide limited insight into outcomes for these groups, and subgroup findings are uncertain due to the modest sample sizes of the research conducted so far.

---

Summary of Research Gaps and Uncertainties

Key research limitation frames include that sample sizes were modest in many of the studies conducted, limiting the generalizability of the reported findings. Findings were mixed across different research settings, suggesting variability in measured outcomes. The findings and design quality were heterogeneous across studies, and research is ongoing to fully contextualize how patients reported their experience.

Key Studies & References

1. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis

Common questions about Albisec (FAQ)

Q: How long does Albisec stay in your system?

A: Studies on the components indicate that the secnidazole active substance has a plasma elimination half-life of approximately 17 hours. The itraconazole component has a terminal half-life that can range from 16 to 28 hours after a single dose. Official restrictions specify avoiding certain substances for up to 48 hours and avoiding breastfeeding for 96 hours. These restrictions relate to the known clearance time of the drug's components.

Q: When should I expect to see the effects of Albisec?

A: The medicine is designed for prompt systemic delivery following the single, high dose. Clinical trials for the secnidazole component typically assessed effectiveness, such as symptom changes and pathogen status, at follow-up intervals ranging from 7 to 21 days after the dose. A precise timeline for the onset of effects is not defined in official regulatory documents.

Q: Is it true that Albisec is a one-time treatment?

A: Official prescribing information confirms that the recommended dosage for this product is structured as a single dose. This pattern aligns with the ultra-short-term course established for the secnidazole component, reflecting the intended use as a rapid intervention.

Q: Is Albisec safe to take if I have liver problems?

A: Official warnings state that caution and close monitoring are required for patients with pre-existing hepatic, or liver, impairment. The medicine is contraindicated for individuals diagnosed with Cockayne Syndrome due to the risk of acute liver failure observed with similar medicines. The conditional nature of these guidelines means a healthcare provider must assess eligibility on a case-by-case basis.

Q: What is the official guidance on using Albisec if I have a history of kidney problems?

A: Official guidance advises that caution and close monitoring are required for patients with pre-existing renal (kidney) impairment. The use of the itraconazole component may be prohibited in combination with certain other drugs, such as colchicine, specifically in patients with documented kidney impairment.

Q: Is it normal to feel dizzy after taking Albisec?

A: Official documents list dizziness as an adverse reaction documented in postmarketing reports. While headache is also listed as a common side effect, dizziness is a nervous system effect associated with the drug and may be experienced by some patients.

Q: Does Albisec interact with common pain relievers like ibuprofen?

A: The itraconazole component acts as a strong inhibitor of the CYP3A4 enzyme, which is critical to how the body processes many other medications. While specific over-the-counter pain relievers may not be individually listed on the label, the potential for interaction depends on whether a co-administered drug is processed by the CYP3A4 system.

Q: Can Albisec cause changes to my urine color?

A: Changes in urine color, such as dark-colored urine, have been reported rarely with the secnidazole component and other related medicines in the nitroimidazole class. This is not listed among the most common adverse reactions documented in clinical trials.

Q: How soon after finishing Albisec can I start using another treatment?

A: The drug is intended as a single, short-term course. Clearance of the secnidazole component is relatively rapid, but the itraconazole component can take 7 to 14 days after discontinuation to fully clear the system. Any decision to begin a new treatment requires assessment by a healthcare provider, based on the clearance time of the drug’s longest-acting component.

Q: Is it possible to be allergic to the inactive ingredients in the Albisec tablet?

A: Official contraindications specifically prohibit the use of the drug in patients with a known history of severe hypersensitivity to the active ingredients (secnidazole, itraconazole) or other related nitroimidazole medicines. Patient counseling information generally advises users to inform their provider about all known allergies, including those to inactive ingredients or excipients.

Q: Can I safely operate machinery after taking Albisec?

A: Documented adverse reactions include nervous system effects such as dizziness and headache. Patients may be affected by these nervous system effects, and caution is advised when performing complex tasks like driving or operating machinery.

Q: Is there a maximum number of times I can take Albisec in a year?

A: The official warning states that the medicine is intended for single-dose, short-term use only. Regulatory documents advise against chronic or repeated use due to a theoretical risk of carcinogenicity observed in animal studies involving related compounds.

Q: Does the drug come in different strengths?

A: Official product information indicates that the recommended dosage is supplied as a single unit-of-use package. This package contains the total required amount of the fixed-dose combination, and other dosage strengths are not specified.

Q: Is there a patient-friendly leaflet for Albisec from a regulatory body?

A: Regulatory requirements mandate that a patient information leaflet or instruction sheet be made available to patients who are dispensed this product. These documents contain essential information on usage, warnings, and potential risks.

Q: Is Albisec effective against infections other than the main ones listed?

A: Official regulatory indications only define the approved uses for the drug, which are related to polymicrobial infections. The regulatory file does not contain evidence that establishes effectiveness against other infections not specified on the label.

Storage and Handling Requirements

Official regulatory documents mandate specific conditions for storing this Fixed-Dose Combination medicine to maintain stability. The product must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F), with permitted excursions.

Storage Restriction	Requirement
Temperature	Store at controlled room temperature; keep from freezing and excessive heat.
Protection	Must be stored away from heat, moisture, and direct light in a closed container.
Packaging	Keep the medicine in its original package (blister pack or carton).
Child Safety	Mandatory to be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Albisec must be disposed of according to local regulations. The best method is to use a drug take-back program. If this option is not available and the medicine is not on the official flush list, it may be discarded in the household trash after mixing it with an undesirable substance (like coffee grounds or kitty litter) and sealing it in a bag.